Patents by Inventor Anjali Pandey

Anjali Pandey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-obesity Potential of Calebin A
    Publication number: 20130012579
    Abstract: The present invention discloses the potential of Calebin A in inhibiting adipogenesis and applications thereof in obesity management. The present invention elucidates the potential of Calebin A to favorably modulate biochemical markers associated with obesity. Notable biomodulatory properties of Calebin A include inhibiting leptin production, increasing adiponectin expression and inhibiting local (adipocyte) and systemic inflammation caused by pro-inflammatory cytokines Tumor Necrosis Factor (TNF-?), Interleukin-6 (IL-6) and Interleukin-1 (IL-1?).
    Type: Application
    Filed: January 10, 2012
    Publication date: January 10, 2013
    Inventors: Muhammed Majeed, Anjali Pandey
  • Inhibitors of syk and JAK protein kinases
    Patent number: 8349860
    Abstract: The present invention is directed to compounds of formula I-V and tautomers thereof or pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of syk kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma.
    Type: Grant
    Filed: October 17, 2011
    Date of Patent: January 8, 2013
    Assignee: Portola Pharmaceuticals, Inc.
    Inventors: Zhaozhong J. Jia, Chandrasekar Venkataramani, Wolin Huang, Mukund Mehrotra, Yonghong Song, Qing Xu, Shawn M. Bauer, Jack W. Rose, Brian Kane, Anjali Pandey
  • Factor XA inhibitors
    Patent number: 8349873
    Abstract: The present invention is directed to compounds of formula (I) and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of Factor Xa. The present invention is also directed to intermediates used in making such compounds, pharmaceutical compositions containing such a compound, methods to prevent or treat a number of conditions characterized by undesired thrombosis and methods of inhibiting the coagulation of a blood sample.
    Type: Grant
    Filed: October 10, 2011
    Date of Patent: January 8, 2013
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Yonghong Song, Zhaozhong J. Jia, Anjali Pandey, Robert M. Scarborough, Carroll Scarborough, legal representative
  • Quinazoline derivatives as kinase inhibitors
    Patent number: 8324205
    Abstract: The present invention relates to nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention is also related to a method of inhibiting kinases and treating disease states in a mammal by inhibiting the phosphorylation of kinases. In a particular aspect the present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which inhibit phosphorylation of a PDGF receptor to hinder abnormal cell growth and cell wandering, and a method for preventing or treating cell-proliferative diseases such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis.
    Type: Grant
    Filed: May 22, 2009
    Date of Patent: December 4, 2012
    Assignees: Millennium Pharmaceuticals, Inc., Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Anjali Pandey, Robert M. Scarborough, Kenji Matsuno, Michio Ichimura, Yuji Nomoto, Shinichi Ide, Eiji Tsukuda, Junko Sasaki, Shoji Oda
  • Inhibitors of SYK and JAK protein kinases
    Patent number: 8318755
    Abstract: The present invention is directed to compounds of formula I-V and tautomers thereof or pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of syk kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma.
    Type: Grant
    Filed: October 7, 2011
    Date of Patent: November 27, 2012
    Assignee: Portola Pharmaceuticals, Inc.
    Inventors: Zhaozhong J. Jia, Chandrasekar Venkataramani, Wolin Huang, Mukund Mehrotra, Yonghong Song, Qing Xu, Shawn M. Bauer, Jack W. Rose, Brian Kane, Anjali Pandey
  • Compositions and methods for inhibiting TGF-?
    Patent number: 8268857
    Abstract: This invention provides compounds that are useful for treating patients having a TGF-?-mediated disease, particularly an ALK5-mediated disease. The compounds are represented by formula I: wherein: a-b is CH2CH2, CH2CH2CH2, CH?CH, CH?N, or N?CH; Z is N or C—F; and G is C1-6 aliphatic or a phenyl, naphthyl, or 5-6 membered heteroaryl ring.
    Type: Grant
    Filed: January 16, 2007
    Date of Patent: September 18, 2012
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Robert M. Scarborough, Anjali Pandey, Meenakshi S. Venkatraman
  • Inhibitors of protein kinases
    Patent number: 8258144
    Abstract: The present invention is directed to compounds of formula I-II and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of syk and/or JAK kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk and/or JAK kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk and/or JAK kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma.
    Type: Grant
    Filed: April 22, 2009
    Date of Patent: September 4, 2012
    Assignee: Portola Pharmaceuticals, Inc.
    Inventors: Yonghong Song, Qing Xu, Shawn M. Bauer, Zhaozhong J. Jia, Mukund Mehrotra, Anjali Pandey
  • BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS
    Publication number: 20120142671
    Abstract: The present invention is directed to compounds of formula I and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of Syk kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition Syk kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by Syk kinase activity, such as Non Hodgkin's Lymphoma.
    Type: Application
    Filed: November 1, 2011
    Publication date: June 7, 2012
    Applicant: Portola Pharmaceuticals, Inc.
    Inventors: Zhaozhong J. Jia, Yonghong Song, Qing Xu, Brian Kane, Shawn M. Bauer, Anjali Pandey
  • [4-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS AND METHODS RELATED THERETO
    Publication number: 20120129876
    Abstract: The present invention provides novel sulfonylurea salts of a salt of formula (I) and polymorph forms thereof. The compounds in their various forms are effective platelet ADP receptor inhibitors and may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also provides a method for preparing such compounds and forms and for preventing or treating thrombosis and thrombosis related conditions in a mammal comprising the step of administering a therapeutically effective amount of a salt of formula (I) or a pharmaceutically acceptable form thereof.
    Type: Application
    Filed: June 22, 2011
    Publication date: May 24, 2012
    Applicant: Portola Pharmaceuticals, Inc.
    Inventors: Emma Sharp, Louisa Jane Quegan, Anjali Pandey, Juan Wang, Matthew Nieder, Wolin Huang
  • INHIBITORS OF SYK AND JAK PROTEIN KINASES
    Publication number: 20120130073
    Abstract: The present invention is directed to compounds of formula I-V and tautomers thereof or pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of syk kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma.
    Type: Application
    Filed: October 7, 2011
    Publication date: May 24, 2012
    Applicant: Portola Pharmaceuticals, Inc.
    Inventors: Zhaozhong Jia, Chandrasekar Venkataramani, Wolin Huang, Mukund Mehrotra, Yonghong Song, Qing Xu, Shawn M. Bauer, Jack W. Rose, Brian Kane, Anjali Pandey
  • INHIBITORS OF PROTEIN KINASES
    Publication number: 20120129867
    Abstract: The present invention is directed to compounds of formula I-II and pharmaceutically acceptable tautomers, salts, or stereoisomers thereof which are inhibitors of syk and/or JAK kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk and/or JAK kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk and/or JAK kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma.
    Type: Application
    Filed: January 30, 2012
    Publication date: May 24, 2012
    Applicant: Portola Pharmaceuticals, Inc.
    Inventors: Shawn M. Bauer, Zhaozhong J. Jia, Yonghong Song, Qing Xu, Mukund Mehrotra, Jack W. Rose, Wolin Huang, Chandrasekar Venkataramani, Anjali Pandey
  • NICOTINAMIDES AS JAK KINASE MODULATORS
    Publication number: 20120108566
    Abstract: The present invention is directed to compounds of formula I and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of JAK kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition JAK kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by JAK kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma.
    Type: Application
    Filed: November 1, 2011
    Publication date: May 3, 2012
    Applicant: Portola Pharmaceuticals, Inc.
    Inventors: Shawn M. Bauer, Yonghong Song, Qing Xu, Jack W. Rose, Zhaozhong J. Jia, Brian Kane, Wolin Huang, Anjali Pandey, Mukund Mehrotra
  • INHIBITORS OF SYK AND JAK PROTEIN KINASES
    Publication number: 20120101275
    Abstract: The present invention is directed to compounds of formula I-V and tautomers thereof or pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of syk kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma.
    Type: Application
    Filed: October 17, 2011
    Publication date: April 26, 2012
    Applicant: Portola Pharmaceuticals, Inc.
    Inventors: Zhaozhong Jia, Chandrasekar Venkataramani, Wolin Huang, Mukund Mehrotra, Yonghong Song, Qing Xu, Shawn M. Bauer, Jack W. Rose, Brian Kane, Anjali Pandey
  • METHODS AND FORMULATIONS OF TREATING THROMBOSIS WITH BETRIXABAN AND A P-GLYCOPROTEIN INHIBITOR
    Publication number: 20120095019
    Abstract: This invention is directed to methods of inhibiting coagulation or treating thrombosis using a factor Xa inhibitor and a P-glycoprotein (Pgp) inhibitor. The invention is also directed to formulations used in the methods.
    Type: Application
    Filed: August 31, 2011
    Publication date: April 19, 2012
    Inventors: Uma Sinha, George A. Mansoor, Anne Hermanowski Vosatka, Vincent R. Capodanno, Robert M. Wenslow, Richard G. Ball, Eric L. Margelefsky, Timothy K. Maher, Itzia Zoraida Arroyo, Brett Lauring, Liam Corcoran, William Denney, Michael McNevin, Anjali Pandey
  • COMPOSITION AND A METHOD OF TREATING CNS DISORDERS AND HYPERPIGMENTATION
    Publication number: 20120088841
    Abstract: The present invention relates to a method of treating CNS disorders, particularly Alzheimer's disease. The method comprise step of administering to a subject in need thereof a therapeutically effective amount of hydroxychavicol and/or its derivatives or a composition comprising hydroxychavicol and/or its derivatives optionally along with pharmaceutically acceptable excipients. The invention also relates to use of hydroxychavicol and/or its derivatives for treating hyperpigmentation.
    Type: Application
    Filed: October 8, 2010
    Publication date: April 12, 2012
    Inventors: Muhammed Majeed, Sarang Bani, Anjali Pandey, Susmitha Anand-Tathapudi
  • FACTOR XA INHIBITORS
    Publication number: 20120088795
    Abstract: The present invention is directed to compounds of formula (I) and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of Factor Xa. The present invention is also directed to intermediates used in making such compounds, pharmaceutical compositions containing such a compound, methods to prevent or treat a number of conditions characterized by undesired thrombosis and methods of inhibiting the coagulation of a blood sample.
    Type: Application
    Filed: October 10, 2011
    Publication date: April 12, 2012
    Inventors: Yonghong Song, Zhaozhong J. Jia, Anjali Pandey, Robert M. Scarborough, Carroll Scarborough
  • CRYSTALLINE FORMS OF A FACTOR Xa INHIBITOR
    Publication number: 20120071519
    Abstract: Provided herein are crystalline forms of a maleate salt of betrixaban, compositions and methods of preparation or use thereof.
    Type: Application
    Filed: August 31, 2011
    Publication date: March 22, 2012
    Inventors: Vincent R. Capodanno, Liam Corcoran, Michael McNevin, Itzia Zoraida Arroyo, Robert M. Wenslow, Richard G. Ball, Eric L. Margelefsky, Timothy K. Maher, Anjali Pandey
  • Inhibitors of protein kinases
    Patent number: 8138339
    Abstract: The present invention is directed to 2-cycloalkylamino-4-arylamino-benzamide compounds of formula I pharmaceutically acceptable salts thereof which are inhibitors of syk and/or JAK kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk and/or JAK kinase activity, and methods to prevent or treat a number of conditions mediated at least in part by syk and/or JAK kinase activity, such as cardiovascular disease, inflammatory disease, autoimmune disease and cell proliferative disorder.
    Type: Grant
    Filed: April 16, 2009
    Date of Patent: March 20, 2012
    Assignee: Portola Pharmaceuticals, Inc.
    Inventors: Shawn M. Bauer, Zhaozhong J. Jia, Yonghong Song, Qing Xu, Mukund Mehrotra, Jack W. Rose, Wolin Huang, Chandrasekar Venkataramani, Anjali Pandey
  • INTRAVENOUS AND ORAL DOSING OF A DIRECT-ACTING AND REVERSIBLE P2Y12 INHIBITOR
    Publication number: 20120009172
    Abstract: The invention provides methods and compositions for rapid and reversible inhibition of platelet aggregation in human subjects in need thereof by administering compounds of the formula: alone or in combination with a second agent which can be aspirin or a thrombolytic agent.
    Type: Application
    Filed: September 16, 2011
    Publication date: January 12, 2012
    Applicant: Portola Pharmaceuticals, Inc.
    Inventors: Daniel D. Gretler, Pamela B. Conley, Patrick Andre, Athiwat Hutchaleelaha, David R. Phillips, Anjali Pandey, Robert M. Scarborough, Carroll Anna Crew Scarborough, Wolin Huang
  • Nitrogenous heterocyclic compounds and process for making nitrogenous heterocyclic compounds and intermediates thereof
    Patent number: RE43098
    Abstract: The present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof and a process for making thereof. The compounds have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention also provides intermediate compounds useful in the process, as well as final products produced by the process, and salts or prodrugs thereof. The invention further provides a method of inhibiting kinases and treating disease states in a mammal by inhibiting the phosphorylation of kinases comprising administering an effective amount of a compound according to the invention to a patient in need thereof.
    Type: Grant
    Filed: October 2, 2007
    Date of Patent: January 10, 2012
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: James Kanter, Anjali Pandey, James Robinson, Robert M. Scarborough, Carroll Scarborough, legal representative